Graft-versus-leukemia effects of transplantation and donor lymphocytes

Hans Jochem Kolb

Research output: Contribution to journalArticlepeer-review

507 Scopus citations

Abstract

Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) effect, but the beneficial effect is limited by graft-versus-host disease (GVHD). Depletion of T cells abrogates GVHD and GVL effects. Delayed transfusion of donor lymphocytes into chimeras after T cell-depleted stem cell transplantation produces a GVL effect without necessarily producing GVHD. Chimerism and tolerance provide a platform for immunotherapy using donor lymphocytes. The allogeneic GVL effects vary from one disease to another, the stage of the disease, donor histocompatibility, the degreeofchimerism, and additional treatment. Immunosuppressive therapy before donor lymphocyte transfusions may augment the effect as well as concomitant cytokine treatment. Possible target antigens are histocompatibility antigens and tumor-associated antigens. Immune escape of tumor cells and changes in the reactivity of T cells are to be considered. Durable responses may be the result of the elimination of leukemia stem cells or the establishment of a durable immune control on their progeny. Recently, we have learned from adoptive immuno-therapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for the effective treatment of leukemia and other malignancies.

Original languageEnglish
Pages (from-to)4371-4383
Number of pages13
JournalBlood
Volume112
Issue number12
DOIs
StatePublished - 1 Dec 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Graft-versus-leukemia effects of transplantation and donor lymphocytes'. Together they form a unique fingerprint.

Cite this